Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
View Patent ↗The present invention relates to the use of pyrido[2,3-d]pyrimidines of formula (I) wherein L, R 1 , R 2 and R 3 have specific meaning. The present invention also relates to the use of the compounds of formula (I) as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds of formula (I) per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
1. A method of inhibiting HCV replication in a mammal infected with HCV, wherein said method comprises the administration of an effective amount of a HCV inhibitory compound, said compound having the formula (I)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, wherein
R 1 is hydrogen, amino, mono- or disubstituted amino, wherein the substituent(s) of the amino may be selected from C 1-6 alkyl, C 2-6 alkenyl,
C 2-6 alkynyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, arylC 1-6 alkyl, wherein the aryl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
L is —NR 8 —, —NR 8 —C 1-6 alkanediyl-, —NR 8 —CO—C 1-6 alkanediyl-, —NR 8 —SO 2 —C 1-6 alkanediyl-, —O—, —O—C 1-6 alkanediyl-, —O—CO—, —O—CO—C 1-6 alkanediyl-, —S—, —S—C 1-6 alkanediyl-, or
wherein the dotted ring together with N and Z form a Het 1 cycle having 5 to 8 members including ring members N and Z, and wherein said L ring is attached to the pyrido[2,3-d]pyrimidine ring by the nitrogen atom;
Z represents N or CH;
R 2 represents hydrogen, hydroxyC 1-6 alkyl, C 3-7 cycloalkyl, aryl, Het 1 , or Het 2 , wherein said C 3-7 cycloalkyl, aryl, Het 1 , and Het 2 are each independently optionally substituted with one or more substituents selected from C 1-4 alkyl, C 2-4 alkenyl,
C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , NR 4a R 4b , —NR 4a COR 6 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , —SO 2 NR 4a R 4b , morpholin-4-yl, phenyl, aminophenyl, and aminophenylcarbonyl, and wherein the C 1-4 alkyl may be further substituted with —COOR 7 ;
R 3 represents C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, Het 1 , Het 2 or Het 2 C 1-6 alkyl, each independently optionally substituted with one or more substituents selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 6 , —NR 4a COOR 7 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , and —SO 2 NR 4a R 4b ;
each R 4a and R 4b is independently hydrogen, C 1-4 alkyl, hydroxyC 1-4 alkyl, Het 1 C 1-4 alkyl, polyhaloC 1-4 alkyl, cyano, or nitro;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl; and
each R 8 is independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl,
C 1-10 alkylcarbonyl, aminoC 1-10 alkyl, aryl, arylcarbonyl, arylC 1-10 alkyl, Het 1 , Het 1 C 1-6 alkyl, or a nitrogen-protecting group, wherein the aryl is optionally substituted with 1 to 3 substituents selected from C 1-4 alkyl, C 2-4 alkenyl,
C 2-4 alkynyl, C 1-4 alkylcarbonyl, phenyl, C 1-4 alkylphenyl, phenylcarbonyl, aminophenyl, aminoC 1-4 alkylphenyl, aminophenylcarbonyl, halo, —OR 6 , —NR 4a R 4b , —SR 5 , —SOR 5 , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SO 2 R 5 , —OCOR 6 , —NR 4a COR 6 ,
—NR 4a CONR 4a R 4b , —NR 4a COOR 6 , —OCONR 4a R 4b , —COOR 6 , —SO 3 R 6 , —CONR 4a R 4b , —SO 2 NR 4a R 4b , cyano, polyhaloC 1-4 alkyl, and nitro;
Het 1 is defined as a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle having ring member sizes selected from the group consisting of 3 to 12 ring members, 5 to 10 ring members and 5 to 8 ring members, which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and which is optionally substituted on one or more carbon atoms by C 1-6 alkyl, C 1-6 alkyloxy, halo, hydroxy, oxo, optionally mono- or disubstituted amino, nitro, cyano, polyhaloC 1-4 alkyl, carboxyl, C 1-6 alkoxycarbonyl, C 3-7 cycloalkyl, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, aryl and a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle having 3 to 12 ring members which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and whereby the optional substituents on any amino function are hydrogen, or C 1-4 alkyl;
Het 2 is defined as an aromatic monocyclic, bicyclic or tricyclic heterocycle having ring member sizes selected from the group consisting of 5 to 14 ring members, 5 to 10 ring members and 5 to 6 ring members, which contains one or more heteroatom ring members each independently selected from nitrogen, oxygen or sulfur, and which is optionally substituted on one or more carbon atoms by C 1-6 alkyl, optionally mono- or disubstituted aminoC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkyloxy, halo, hydroxy, optionally mono- or disubstituted amino, nitro, cyano, polyhaloC 1-4 alkyl, carboxyl, C 1-6 alkoxycarbonyl, C 3-7 cycloalkyl, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, aryl, Het 1 and an aromatic monocyclic, bicyclic or tricyclic heterocycle having 5 to 12 ring members; whereby the optional substituents on any amino function are hydrogen, or C 1-4 alkyl;
aryl is defined as phenyl.
2. The method of inhibiting HCV replication according to claim 1 , wherein the compound has the formula (II)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, and further wherein
R 9 represents C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 6 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , —SO 2 NR 4a R 4b , morpholin-4-yl, phenyl, aminophenyl, or aminophenyl-carbonyl, and wherein the C 1-4 alkyl may be further substituted with —COOR 7 ; and
n is 0, 1, 2, 3, or 4.
3. The method of inhibiting HCV replication of claim 1 , wherein the compound has the formula (III)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, and further wherein
R 10 represents C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b ,
—NR 4a COR 6 , —NR 4a COOR 7 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , and —SO 2 NR 4a R 4b ; and
m is 0, 1, 2, 3, or 4.
4. The method of inhibiting HCV replication according to claim 3 , wherein the compound has the formula (IV)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, and further wherein
R 9 represents C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 6 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , —SO 2 NR 4a R 4b , morpholin-4-yl, phenyl, aminophenyl, or aminophenyl-carbonyl, and wherein the C 1-4 alkyl may be further substituted with —COOR 7 ; and
n is 0, 1, 2, 3, or 4.
5. The method of inhibiting HCV replication according to claim 1 , wherein the compound has the formula (V)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, and further wherein
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 6 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , —SO 2 NR 4a R 4b , morpholin-4-yl, phenyl, aminophenyl, or aminophenylcarbonyl, and wherein the C 1-4 alkyl may be further substituted with —COOR 7 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
6. The method of inhibiting HCV replication according to claim 5 , wherein
R 1 is hydrogen, amino, mono- or disubstituted amino, wherein the substituents of the amino may be selected from C 1-6 alkyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
each R 4a and R 4b is independently hydrogen, or C 1-4 alkyl;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , polyhaloC 1-4 alkyl, halo, —COR 6 , —COOR 7 , —OR 7 , —NR 4a R 4b , —NR 4a SO 2 R 5 , —SR 5 , —SO 2 R 5 , or —SO 2 NR 4a R 4b ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
7. The method of inhibiting HCV replication according to claim 5 , wherein
R 1 is hydrogen, amino, mono- or disubstituted amino, wherein the substituents of the amino may be selected from C 1-6 alkyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , polyhaloC 1-4 alkyl, halo, —COR 6 , —COOR 7 ,
—OR 7 , —SR 5 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
8. The method of inhibiting HCV replication according to claim 5 , wherein
R 1 is hydrogen, amino, monosubstituted amino, wherein the substituents of the amino may be selected from C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkoxy;
each R 5 is C 1-4 alkyl;
each R 7 is C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , polyhaloC 1-4 alkyl, halo, —COOR 7 , —OR 7 , —SR 5 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
9. The method of inhibiting HCV replication according to claim 5 , wherein
R 1 is hydrogen, amino, monosubstituted amino, wherein the substituents of the amino may be selected from C 1-4 alkyloxyC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkoxy;
each R 5 is C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , halo, —OR 7 , or —SR 5 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
10. The method of inhibiting HCV replication according to claim 1 , wherein
R 1 is hydrogen, or amino;
each R 5 is C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl, —OR 7 , or —SR 5 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
11. The method of inhibiting HCV replication according to claim 1 , wherein the nitrogen-protecting group is C 1-6 alkyloxycarbonyl, arylmethoxycarbonyl, trifluoroacetyl, or arylmethyl.
12. The method of inhibiting HCV replication according to claim 1 , wherein the nitrogen-protecting group is t-butoxycarbonyl, benzyloxycarbonyl, benzyl, or trifluoromethyl.
13. A compound of the formula (V)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, wherein
R 1 is amino, or mono- or disubstituted amino, wherein the substituents of the amino may be selected from C 1-6 alkyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
each R 4a and R 4b is independently hydrogen, or C 1-4 alkyl;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , polyhaloC 1-4 alkyl, halo, —COR 6 , —OR 7 , —NR 4a R 4b , —NR 4a SO 2 R 5 , —SR 5 , —SO 2 R 5 , or —SO 2 NR 4a R 4b ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
14. A compound according to claim 13 , wherein
R 1 is amino, or mono- or disubstituted amino, wherein the substituents of the amino may be selected from C 1-6 alkyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
each R 4a , R 4b , R 5 , R 7 , independently, is hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl, halo, —OR 7 , or —SR 5 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
15. A compound according to claim 13 , wherein
R 1 is amino;
each R 4a , R 4b , R 5 , R 7 , independently, is hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl, halo, —OR 7 , or —SR 5 ;
R 13 represents hydrogen, or halo; and
R 14 represents halo.
16. A compound according to claim 13 , wherein
R 11 is hydrogen; and
R 12 is C 1-4 alkyl, halo, C 1-4 alkoxy, C 1-4 alkylthio, or trifluoromethyl.
17. A compound according to claim 13 , wherein
R 13 and R 14 represent halo.
18. A compound according to claim 13 , wherein the nitrogen-protecting group is C 1-6 alkyloxycarbonyl, arylmethoxycarbonyl, trifluoroacetyl, or arylmethyl.
19. A compound according to claim 13 , wherein the nitrogen-protecting group is t-butoxycarbonyl, benzyloxycarbonyl, benzyl, or trifluoromethyl.
20. A pharmaceutical composition comprising a compound of formula (V)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, wherein
R 1 is amino, or mono- or disubstituted amino, wherein the substituents of the amino may be selected from C 1-6 alkyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
each R 4a and R 4b is independently hydrogen, or C 1-4 alkyl;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , polyhaloC 1-4 alkyl, halo, —COR 6 , —OR 7 , —NR 4a R 4b , —NR 4a SO 2 R 5 , —SR 5 , —SO 2 R 5 , or —SO 2 NR 4a R 4b ;
R 13 represents hydrogen, or halo;
R 14 represents halo; and at least one pharmaceutically acceptable excipient.
21. A pharmaceutical composition comprising a compound of formula (V)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, wherein
R 1 is amino, or mono- or disubstituted amino, wherein the substituents of the amino may be selected from C 1-6 alkyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, phenylC 1-6 alkyl, wherein the phenyl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
each R 4a and R 4b is independently hydrogen, or C 1-4 alkyl;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl;
R 8 is hydrogen, or a nitrogen-protecting group;
each R 11 and R 12 represent, independently, hydrogen, C 1-4 alkyl which may be further substituted with —COOR 7 , polyhaloC 1-4 alkyl, halo, —COR 6 , —OR 7 , —NR 4a R 4b , —NR 4a SO 2 R 5 , SR 5 , —SO 2 R 5 , or —SO 2 NR 4a R 4b ;
R 13 represents hydrogen, or halo;
R 14 represents halo, and further comprising one or more other anti-HCV agents.
22. A method of treating a mammal infected with HCV, wherein said method comprises the administration of an effective amount of a HCV inhibitory compound, said compound having the formula (I)
or an N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, wherein
R 1 is hydrogen, amino, mono- or disubstituted amino, wherein the substituent(s) of the amino may be selected from C 1-6 alkyl, C 2-6 alkenyl,
C 2-6 alkynyl, C 1-4 alkyloxyC 1-4 alkyl, diC 1-4 alkylaminoC 1-4 alkyl, piperidin-1-yl-C 1-4 alkyl, arylC 1-6 alkyl, wherein the aryl group may be further substituted with C 1-4 alkyl, or C 1-4 alkoxy;
L is —NR 8 —, —NR 8 —C 1-6 alkanediyl-, —NR 8 —CO—C 1-6 alkanediyl-, —NR 8 —SO 2 —C 1-6 alkanediyl-, —O—, —O—C 1-6 alkanediyl-, —O—CO—, —O—CO—C 1-6 alkanediyl-, —S—, —S—C 1-6 alkanediyl-, or
wherein the dotted ring together with N and Z form a Het 1 cycle having 5 to 8 members including ring members N and Z, and wherein said L ring is attached to the pyrido[2,3-d]pyrimidine ring by the nitrogen atom;
Z represents N or CH;
R 2 represents hydrogen, hydroxyC 1-6 alkyl, C 3-7 cycloalkyl, aryl, Het 1 , or Het 2 , wherein said C 3-7 cycloalkyl, aryl, Het 1 , and Het 2 are each independently optionally substituted with one or more substituents selected from C 1-4 alkyl, C 2-4 alkenyl,
C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 6 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , —SO 2 NR 4a R 4b , morpholin-4-yl, phenyl, aminophenyl, and aminophenylcarbonyl, and wherein the C 1-4 alkyl may be further substituted with —COOR 7 ;
R 3 represents C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, Het 1 , Het 2 or Het 2 C 1-6 alkyl, each independently optionally substituted with one or more substituents selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, polyhaloC 1-4 alkyl, halo, cyano, nitro, —COR 6 , —COOR 7 , —CONR 4a R 4b , —OR 7 , —OCOR 6 , —OCONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 6 , —NR 4a COOR 7 , —NR 4a CONR 4a R 4b , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SR 5 , —SOR 7 , —SO 2 R 5 , —SO 3 R 7 , and —SO 2 NR 4a R 4b ;
each R 4a and R 4b is independently hydrogen, C 1-4 alkyl, hydroxyC 1-4 alkyl, Het 1 C 1-4 alkyl, polyhaloC 1-4 alkyl, cyano, or nitro;
each R 5 is independently hydrogen, or C 1-4 alkyl;
each R 6 is independently hydrogen, or C 1-4 alkyl;
each R 7 is independently hydrogen, or C 1-4 alkyl; and
each R 8 is independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl,
C 1-10 alkylcarbonyl, aminoC 1-10 alkyl, aryl, arylcarbonyl, arylC 1-10 alkyl, Het 1 , Het 1 C 1-6 alkyl, or a nitrogen-protecting group, wherein the aryl is optionally substituted with 1 to 3 substituents selected from C 1-4 alkyl, C 2-4 alkenyl,
C 2-4 alkynyl, C 1-4 alkylcarbonyl, phenyl, C 1-4 alkylphenyl, phenylcarbonyl, aminophenyl, aminoC 1-4 alkylphenyl, aminophenylcarbonyl, halo, —OR 6 , —NR 4a R 4b , —SR 5 , —SOR 5 , —NR 4a SOR 5 , —NR 4a SO 2 R 5 , —SO 2 R 5 , —OCOR 6 , —NR 4a COR 6 , —NR 4a CONR 4a R 4b , —NR 4a COOR 6 , —OCONR 4a R 4b , COOR 6 , —SO 3 R 6 , —CONR 4a R 4b , —SO 2 NR 4a R 4b , cyano, polyhaloC 1-4 alkyl, and nitro;
Het 1 is defined as a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle having ring member sizes selected from the group consisting of 3 to 12 ring members, 5 to 10 ring members and 5 to 8 ring members, which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and which is optionally substituted on one or more carbon atoms by C 1-6 alkyl, C 1-6 alkyloxy, halo, hydroxy, oxo, optionally mono- or disubstituted amino, nitro, cyano, polyhaloC 1-4 alkyl, carboxyl, C 1-6 alkoxycarbonyl, C 3-7 cycloalkyl, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, aryl and a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle having 3 to 12 ring members which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and whereby the optional substituents on any amino function are hydrogen, or C 1-4 alkyl;
Het 2 is defined as an aromatic monocyclic, bicyclic or tricyclic heterocycle having ring member sizes selected from the group consisting of 5 to 14 ring members, 5 to 10 ring members and 5 to 6 ring members, which contains one or more heteroatom ring members each independently selected from nitrogen, oxygen or sulfur, and which is optionally substituted on one or more carbon atoms by C 1-6 alkyl, optionally mono- or disubstituted aminoC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkyloxy, halo, hydroxy, optionally mono- or disubstituted amino, nitro, cyano, polyhalo-C 1-4 alkyl, carboxyl, C 1-6 alkoxycarbonyl, C 3-7 cycloalkyl, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, aryl, Het 1 and an aromatic monocyclic, bicyclic or tricyclic heterocycle having 5 to 12 ring members; whereby the optional substituents on any amino function are hydrogen, or C 1-4 alkyl;
aryl is defined as phenyl.